<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087773</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2017-01</org_study_id>
    <nct_id>NCT03087773</nct_id>
  </id_info>
  <brief_title>Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction</brief_title>
  <acronym>EMMY</acronym>
  <official_title>Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United Arab Emirates University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Landeskrankenhaus Feldkirch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paracelsus Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Rudolfstiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Klagenfurt am Wörthersee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barmherzige Brüder Eisenstadt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kardinal Schwarzenberg Klinikum Schwarzach St. Veit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johannes Kepler University of Linz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Landesklinikum Sankt Polten</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Landeskrankenhaus II Graz West</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is planned to investigate the impact of Empagliflozin on biomarkers of heart
      failure in patients with myocardial infarction with and without type 2 diabetes mellitus
      within 6 months after the event.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is associated with an about two to three-fold increased risk
      for cardiovascular events as compared to subjects without diabetes.

      Sodium-dependent glucose cotransporter 2 (SGLT-2) is mainly expressed in human kidneys and
      small intestinal cells. In the proximal tubule of the nephron SGLT-2 is responsible for the
      reabsorption of approximately 90% of the filtrated glucose. Inhibition of SGLT-2 was shown to
      increase renal glucose excretion and to lower glucose. Subsequently, a number of SGLT-2
      inhibitors were developed and are currently approved for the treatment of type 2 diabetes.

      Recently, Zinman et al published the results of the EMPA-REG-OUTCOME (Cardiovascular Outcome
      Event Trial in Type 2 Diabetes Mellitus Patient) trial where the cardiovascular impact of a
      glucose lowering regimen including Empagliflozin as compared to usual glucose control without
      an SGLT-2 inhibitor was investigated. The trial demonstrated an unexpected reduction in the
      primary composite endpoint, comprising cardiovascular death, non-fatal myocardial infarction
      and non-fatal stroke. The reduction was mainly driven by a 38% relative risk reduction in
      cardiovascular deaths; moreover they demonstrated an impressive 35% relative risk reduction
      in the secondary endpoint hospitalization for heart failure. Of note, the beneficial effects
      observed in the Empagliflozin group seem to occur very rapidly after commencing the
      treatment, as suggested by the early separation of the Kaplan-Meier curves. However, the
      mechanisms responsible for this finding remain unclear. Diuretic effects with subsequent
      impact on hemodynamics or potential cardioprotective effects of glucagon, which levels rise
      under the treatment with SGLT-2 inhibitors and the resulting rise in ketone bodies or a small
      increase in hematocrit have been suggested.

      The aim of our trial is to investigate whether Empagliflozin treatment commenced within 72-h
      after acute myocardial infarction has an impact on heart failure in subjects with and without
      diabetes mellitus type 2.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2017</start_date>
  <completion_date type="Anticipated">April 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of nt-proBNP levels</measure>
    <time_frame>26 weeks</time_frame>
    <description>Difference in the change of nt-proBNP levels between treatment groups from randomization to week 26</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of ejection fraction</measure>
    <time_frame>26 weeks</time_frame>
    <description>Difference in the change of ejection fraction between treatment groups from randomization to week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of ejection fraction</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the change of ejection fraction between treatment groups from randomization to week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of left ventricular diastolic function</measure>
    <time_frame>26 weeks</time_frame>
    <description>Difference in the change of left ventricular diastolic function from randomization to week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of left ventricular diastolic function</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the change of left ventricular diastolic function from randomization to week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of nt-proBNP levels</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the change of nt-proBNP levels between treatment groups from randomization to week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of HbA1c</measure>
    <time_frame>26 weeks</time_frame>
    <description>Difference in the change of HbA1c between treatment groups from randomization to week 26 (in subjects with known diabetes mellitus Type 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of body weight</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the change of body weight between treatment groups from randomization to week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of body weight</measure>
    <time_frame>26 weeks</time_frame>
    <description>Difference in the change of body weight between treatment groups from randomization to week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of blood beta-hydroxybutyrate levels</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the change of blood beta-hydroxybutyrate levels between the treatment groups from randomization to week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of blood beta-hydroxybutyrate levels</measure>
    <time_frame>26 weeks</time_frame>
    <description>Difference in the change of blood beta-hydroxybutyrate levels between the treatment groups from randomization to week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hospital re-admissions due to heart failure</measure>
    <time_frame>30 weeks</time_frame>
    <description>Difference in the number of hospital re-admissions due to heart failure between the treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hospital re-admissions for any cause</measure>
    <time_frame>30 weeks</time_frame>
    <description>Difference in the number of hospital re-admissions for any cause between the treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospital stay</measure>
    <time_frame>30 weeks</time_frame>
    <description>Difference in the duration of hospital stay between the treatment groups after initiation of the study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">476</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects will receive Empagliflozin 10mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 mg</intervention_name>
    <description>The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>The subject will receive Placebo orally once daily for 26 weeks.</description>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Myocardial infarction with evidence of significant myocardial necrosis defined as a
             rise in creatinine kinase &gt;800 U/l and a troponin T-level (or troponin I-level) &gt;10x
             ULN (upper limit of normal). In addition at least 1 of the following criteria must be
             the met:

               -  Symptoms of ischemia

               -  ECG (electrocardiogram) changes indicative of new ischemia (new ST-T changes or
                  new LBBB)

               -  Imaging evidence of new regional wall motion abnormality

          2. 18 - 80 years of age

          3. Informed consent has to be given in written form

          4. eGFR (glomerular filtration rate) &gt; 45 ml/min/1.73m2

          5. Blood pressure before first drug dosing: RR systolic &gt;110 mmHg

          6. Blood pressure before first drug dosing: RR diastolic &gt;70 mmHg

          7. ≤72h after myocardial infarction (after the performance of a coronary angiography)

        Exclusion Criteria:

          1. Any other form of diabetes mellitus than type 2 diabetes mellitus, history of diabetic
             ketoacidosis

          2. Blood pH (potential hydrogen) &lt; 7,32

          3. Known allergy to SGLT-2 inhibitors

          4. Hemodynamic instability as defined by intravenous administration of catecholamine,
             calcium sensitizers or phosphodiesterase inhibitors

          5. &gt;1 episode of severe hypoglycemia within the last 6 months and treatment with insulin
             or sulfonylurea

          6. Females of childbearing potential without adequate contraceptive methods (i.e.
             sterilization, intrauterine device, vasectomized partner; or medical history of
             hysterectomy)

          7. Acute symptomatic urinary tract infection (UTI) or genital infection

          8. Patients currently being treated with any SGLT-2 inhibitor or having received
             treatment with any SGLT-2 inhibitor within the 4 weeks prior to the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Sourij, Assoc.-Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk von Lewinski, Assoc.-Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harald Sourij, Assoc.-Prof.</last_name>
    <phone>+43 316 385 78038</phone>
    <phone_ext>81310</phone_ext>
    <email>ha.sourij@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Norbert J Tripolt, PhD</last_name>
    <phone>+43 316 385</phone>
    <phone_ext>78038</phone_ext>
    <email>norbert.tripolt@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barmherzige Brüder Eisenstadt</name>
      <address>
        <city>Eisenstadt</city>
        <state>Burgenland</state>
        <zip>7000</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Berger, Univ.-Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt am Wörthersee</name>
      <address>
        <city>Klagenfurt</city>
        <state>Kärnten</state>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannes Alber, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum St. Pölten</name>
      <address>
        <city>St.Pölten</city>
        <state>Niederösterreich</state>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deddo Mörtl, Priv.-Doz.MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barmherzige Brüder Linz</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Linz</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Steinwender, Univ.-Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kardinal schwarzenberg Klinikum Schwarzach</name>
      <address>
        <city>Schwarzach Im Pongau</city>
        <state>Salzburg</state>
        <zip>5620</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Mayrhofer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VIVIT Institut am akademischen Lehrkrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Säly, Univ.-Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Graz II Standort West</name>
      <address>
        <city>Graz</city>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter M Zechner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk von Lewinski, Assoc.-Prof.</last_name>
      <email>dirk.von-lewinski@medunigraz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uta Hoppe, Univ.-Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Rudolfstiftung</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz Weidinger, Univ.-Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AKH Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolanta Siller-Matula, Assoc.-Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biomarker</keyword>
  <keyword>Heart failure</keyword>
  <keyword>SGLT-2 inhibitor</keyword>
  <keyword>Empagliflozin</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

